Payment overview · 2025
General Payments
$674.02
32 reported records · 12 companies
Healthcare provider profile · identity verified
Stephen D Harrison, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FULTON, IL · NPI 1649221508
Verified facts
What the public records show
CMS Open Payments records show Stephen D Harrison, M.D. received $674.02 in general payments during 2025 across 32 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 580 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 580 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $127.89 | 19.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $88.72 | 13.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.05 | 12.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.79 | 12.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.66 | 7.5% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $47.14 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.54 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.87 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.03 | 5.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.52 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.03 | 4.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.78 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $562.57 | 31 |
| Education | $111.45 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $88.72 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $80.79 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.66 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $47.14 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $47.14 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 580 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
580 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
580 | 72 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 968 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 940 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 929 | 158 |
| Potassium Chloride | Potassium Chloride | 640 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 583 | 116 |
| Eliquis | Apixaban | 580 | 72 |
| Omeprazole | Omeprazole | 549 | 123 |
| Lisinopril | Lisinopril | 545 | 114 |
| Gabapentin | Gabapentin | 499 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 486 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 482 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 95 |
| Sertraline Hcl | Sertraline Hcl | 440 | 65 |
| Metformin Hcl | Metformin Hcl | 418 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 402 | 93 |
| Spironolactone | Spironolactone | 384 | 72 |
| Losartan Potassium | Losartan Potassium | 349 | 77 |
| Trazodone Hcl | Trazodone Hcl | 347 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 69 |
| Lorazepam | Lorazepam | 326 | 53 |
| Prednisone | Prednisone | 326 | 124 |
| Tramadol Hcl | Tramadol Hcl | 318 | 77 |
| Quetiapine Fumarate | Quetiapine Fumarate | 291 | 58 |
| Famotidine | Famotidine | 289 | 53 |
| Mirtazapine | Mirtazapine | 284 | 60 |
| Simvastatin | Simvastatin | 277 | 60 |
| Alprazolam | Alprazolam | 250 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 250 | 58 |
| Finasteride | Finasteride | 237 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 208 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 198 | 28 |
| Donepezil Hcl | Donepezil Hcl | 197 | 31 |
| Allopurinol | Allopurinol | 196 | 41 |
| Myrbetriq | Mirabegron | 194 | 20 |
| Cephalexin | Cephalexin | 187 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 51 |
| Bupropion Xl | Bupropion Hcl | 182 | 32 |
| Carvedilol | Carvedilol | 177 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 33 |
| Xarelto | Rivaroxaban | 157 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 145 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 61 |
| Ropinirole Hcl | Ropinirole Hcl | 135 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 30 |
| Warfarin Sodium | Warfarin Sodium | 132 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 131 | 48 |
| Jardiance | Empagliflozin | 128 | 28 |
| Levetiracetam | Levetiracetam | 127 | 18 |
| Sucralfate | Sucralfate | 127 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 126 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 25 |
| Montelukast Sodium | Montelukast Sodium | 122 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 120 | 52 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 117 | 22 |
| Buspirone Hcl | Buspirone Hcl | 116 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | 20 |
| Memantine Hcl | Memantine Hcl | 115 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 113 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 99 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 93 | 43 |
| Glipizide | Glipizide | 92 | 16 |
| Clonazepam | Clonazepam | 90 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 89 | 12 |
| Aripiprazole | Aripiprazole | 87 | 18 |
| Digoxin | Digoxin | 87 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 66 |
| Januvia | Sitagliptin Phosphate | 87 | suppressed |
| Latanoprost | Latanoprost | 86 | 13 |
| Glimepiride | Glimepiride | 85 | 20 |
| Ozempic | Semaglutide | 82 | 18 |
| Amoxicillin | Amoxicillin | 80 | 47 |
| Alendronate Sodium | Alendronate Sodium | 79 | suppressed |
| Fluconazole | Fluconazole | 78 | 25 |
| Sotalol | Sotalol Hcl | 78 | 19 |
| Pregabalin | Pregabalin | 76 | 12 |
| Baclofen | Baclofen | 74 | 22 |
| Nystatin | Nystatin | 74 | 30 |
| Meloxicam | Meloxicam | 73 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Risperidone | Risperidone | 64 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 11 |
| Bumetanide | Bumetanide | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Cilostazol | Cilostazol | 61 | suppressed |
| Olanzapine | Olanzapine | 61 | suppressed |
| Lansoprazole | Lansoprazole | 60 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 39 |
| Lamotrigine | Lamotrigine | 58 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 57 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 38 |
| Atenolol | Atenolol | 55 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Methylprednisolone | Methylprednisolone | 51 | 40 |
| Temazepam | Temazepam | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 13 |
| Midodrine Hcl | Midodrine Hcl | 49 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 11 |
| Fentanyl | Fentanyl | 46 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 14 |
| Nitroglycerin | Nitroglycerin | 45 | 40 |
| Ramipril | Ramipril | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | 11 |
| Nyamyc | Nystatin | 44 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 17 |
| Lactulose | Lactulose | 41 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 40 | 12 |
| Ibuprofen | Ibuprofen | 40 | 11 |
| Metolazone | Metolazone | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Azithromycin | Azithromycin | 34 | 27 |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 20 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 11 |
| Ketoconazole | Ketoconazole | 30 | 20 |
| Liothyronine Sodium | Liothyronine Sodium | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 13 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Sulfasalazine | Sulfasalazine | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 12 |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Fetzima | Levomilnacipran Hcl | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | 14 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 15 |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Nystop | Nystatin | 15 | 12 |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 14 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $674.02 · 32 records | Teva Pharmaceuticals USA, Inc. | ARISTADA, AUSTEDO XR, Auvelity, Cologuard Collection Kit, ELIQUIS, JARDIANCE, KISUNLA, Kerendia, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error